Protalix BioTherapeutics (PLX) Competitors

$2.40 -0.01 (-0.58%)

As of 09:52 AM Eastern

PLX vs. AURA, CADL, DRUG, GYRE, and MNPR

Should you buy Protalix BioTherapeutics stock or one of its competitors? MarketBeat compares Protalix BioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protalix BioTherapeutics include Aura Biosciences (AURA), Candel Therapeutics (CADL), Bright Minds Biosciences (DRUG), Gyre Therapeutics (GYRE), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.

How does Protalix BioTherapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Aura Biosciences currently has a consensus price target of $20.50, suggesting a potential upside of 196.89%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 400.83%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Aura Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, Aura Biosciences' average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score.

Company	Overall Sentiment
Aura Biosciences	Neutral
Protalix BioTherapeutics	Neutral

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Protalix BioTherapeutics	$76.38M	2.53	$8.31M	$0.18	13.31

Summary

Protalix BioTherapeutics beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protalix BioTherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 400.83%. Candel Therapeutics has a consensus target price of $18.57, suggesting a potential upside of 86.27%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Protalix BioTherapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.53	$8.31M	$0.18	13.31
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Candel Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Candel Therapeutics had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Candel Therapeutics and 0 mentions for Protalix BioTherapeutics. Candel Therapeutics' average media sentiment score of 0.45 beat Protalix BioTherapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Candel Therapeutics	Neutral

Summary

Protalix BioTherapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Bright Minds Biosciences currently has a consensus target price of $143.83, suggesting a potential upside of 89.06%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 400.83%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bright Minds Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Bright Minds Biosciences' return on equity of -20.58% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, Bright Minds Biosciences had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for Protalix BioTherapeutics. Bright Minds Biosciences' average media sentiment score of 0.77 beat Protalix BioTherapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
Protalix BioTherapeutics	Neutral

Protalix BioTherapeutics has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Protalix BioTherapeutics	$76.38M	2.53	$8.31M	$0.18	13.31

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Bright Minds Biosciences and Protalix BioTherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Protalix BioTherapeutics has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.53	$8.31M	$0.18	13.31
Gyre Therapeutics	$117.05M	5.70	$5.03M	-$0.09	N/A

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 400.83%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 183.85%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gyre Therapeutics has a net margin of -5.44% compared to Protalix BioTherapeutics' net margin of -21.03%. Gyre Therapeutics' return on equity of 3.13% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, Gyre Therapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for Gyre Therapeutics and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Gyre Therapeutics	Neutral

Summary

Gyre Therapeutics beats Protalix BioTherapeutics on 9 of the 14 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Monopar Therapeutics had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 0 mentions for Protalix BioTherapeutics. Monopar Therapeutics' average media sentiment score of 0.65 beat Protalix BioTherapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Monopar Therapeutics	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Monopar Therapeutics' return on equity of -12.84% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Protalix BioTherapeutics has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.53	$8.31M	$0.18	13.31
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Protalix BioTherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 400.83%. Monopar Therapeutics has a consensus price target of $108.75, indicating a potential downside of 0.12%. Given Protalix BioTherapeutics' higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Monopar Therapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$193.37M	$350.81M	$6.89B	$23.42B
Dividend Yield	N/A	N/A	2.67%	4.15%
P/E Ratio	-18.46	N/A	27.07	30.65
Price / Sales	2.53	188.69	519.31	20.32
Price / Cash	17.80	22.44	26.68	18.81
Price / Book	5.10	4.90	10.62	4.74
Net Income	$8.31M	-$141.03M	$3.60B	$1.07B
7 Day Performance	3.72%	-1.57%	-1.26%	-0.46%
1 Month Performance	7.93%	-1.20%	1.07%	0.67%
1 Year Performance	57.63%	39.38%	23.63%	16.45%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.4847 of 5 stars	$2.40 -0.6%	$12.00 +400.8%	+66.2%	$193.37M	$76.38M	N/A	200
AURA Aura Biosciences	1.5858 of 5 stars	$7.00 flat	$20.50 +192.9%	+1.6%	$723.73M	N/A	N/A	50
CADL Candel Therapeutics	2.8373 of 5 stars	$9.87 +2.4%	$18.57 +88.2%	+42.0%	$723.18M	N/A	N/A	60	Positive News Analyst Downgrade
DRUG Bright Minds Biosciences	2.5007 of 5 stars	$74.03 -2.5%	$143.83 +94.3%	+185.2%	$720.31M	N/A	N/A	N/A
GYRE Gyre Therapeutics	1.678 of 5 stars	$6.34 flat	$17.00 +168.1%	-18.4%	$706.85M	$116.59M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. AURA, CADL, DRUG, GYRE, and MNPR

How does Protalix BioTherapeutics compare to Aura Biosciences?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Summary

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. AURA, CADL, DRUG, GYRE, and MNPR

How does Protalix BioTherapeutics compare to Aura Biosciences?

Do analysts rate AURA or PLX?

Is AURA or PLX more profitable?

Does the media prefer AURA or PLX?

Do institutionals & insiders hold more shares of AURA or PLX?

Which has preferable valuation & earnings, AURA or PLX?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Do institutionals and insiders hold more shares of PLX or CADL?

Do analysts rate PLX or CADL?

Which has better valuation and earnings, PLX or CADL?

Is PLX or CADL more profitable?

Does the media prefer PLX or CADL?

Summary

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Do analysts prefer DRUG or PLX?

Is DRUG or PLX more profitable?

Does the media favor DRUG or PLX?

Which has higher valuation & earnings, DRUG or PLX?

Do institutionals & insiders hold more shares of DRUG or PLX?

Summary

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Which has higher earnings & valuation, PLX or GYRE?

Do institutionals and insiders believe in PLX or GYRE?

Do analysts prefer PLX or GYRE?

Is PLX or GYRE more profitable?

Does the media favor PLX or GYRE?

Summary

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Does the media prefer PLX or MNPR?

Is PLX or MNPR more profitable?

Which has higher valuation and earnings, PLX or MNPR?

Do analysts recommend PLX or MNPR?

Do institutionals & insiders believe in PLX or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools